Cadence and NVIDIA Unveil Groundbreaking Generative AI and Accelerated Compute-Driven Innovations

Find the Latest SoC Solutions
for... Automotive... IoT... Security... Audio... Video

Cadence Reality Digital Twin Platform integrated with NVIDIA Omniverse and Orion molecular design platform accelerated with NVIDIA BioNeMo will transform the future of design

www.cadence.com/en_US/home.html, Mar. 18, 2024 – 

SAN JOSE, Calif.– Cadence Design Systems, Inc. (Nasdaq: CDNS) today announced an expansion of its multi-year collaboration with NVIDIA across EDA, system design and analysis, digital biology and AI with the unveiling of two transformative solutions to reinvent design using accelerated computing and generative AI.

First, the new Cadence® Reality™ Digital Twin Platform is the industry's pioneering comprehensive digital twin solution to facilitate speed-of-light acceleration of the design, simulation and optimization of data centers across multiple industries. The platform virtualizes the entire data center and uses AI, high-performance computing (HPC) and physics-based simulation to significantly improve data center energy efficiency by up to 30%.

The Cadence Reality platform's integration with NVIDIA Omniverse™ brings OpenUSD data interoperability and physically based rendering to the digital twin solution–helping accelerate data center design and simulation workflows by 30X.

Second, the companies are collaborating on generative AI to dramatically accelerate approaches to drug discovery. Cadence's cloud-native molecular design platform Orion® will now be supercharged with NVIDIA's generative AI tool, NVIDIA BioNeMo™ , and NVIDIA microservices for drug discovery to broaden therapeutic design capabilities and shorten time to trusted results. The collaboration brings together decades of expertise in scientific software and accelerated computing from the two companies to deliver transformative approaches to drug discovery. Accelerated by on-demand GPU access at an unprecedented scale, pharmaceutical companies can quickly and reliably generate and assess design hypotheses across a range of therapeutic modalities, including biologics, peptides and small molecules.

click here to read more...

 Back